Serapha Bio

Name

Serapha Bio

Legal name

Serapha Bio Inc.

Website

https://seraphabio.com

Company type

Private

Founded year

2026

Operating status

Operating

Ownership category

akta.pro rank

Product category

Gene Editing Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Base editing therapy
• Gene editing biotechnology
• Rare disease therapeutics
• Alpha-1 antitrypsin treatment
• Clinical stage biopharmaceutical

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Not yet commercial: Serapha Bio is a pre-commercial biotech company. The company has not yet generated product revenue and appears to be in the development stage, pending the completion of its merger with Boundless Bio.

Core offering

Serapha Bio is a clinical-stage biotechnology company developing a base-editing gene therapy to treat Alpha-1 Antitrypsin Deficiency, a rare genetic disorder caused by mutations in the SERPINA1 gene. The company's lead therapeutic candidate employs base-editing technology to correct the disease-causing mutation, with the intent to provide a disease-modifying treatment for affected patients.

Product overview

Serapha Bio is a biotech company. The source data does not provide specific details on its product portfolio, platform architecture, or individual product/module names. The company announced a merger agreement with Boundless Bio with a concurrent $230 million private placement.

Differentiator

Problem solved

Functional benefit

Products and services

• Base-editing therapy for Alpha-1 Antitrypsin Deficiency An investigational base-editing gene therapy designed to correct the SERPINA1 gene mutation causing Alpha-1 Antitrypsin Deficiency. It is intended for patients with this rare hereditary disorder characterized by lung and liver disease.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Boundless Bio IncflagshipStrategic or Co-development Partner · 23 June 2026Serapha Bio announced a definitive merger agreement with Boundless Bio Inc on June 23, 2026. The transaction includes a concurrent private placement of $230 million. This is the company's primary strategic transaction, representing a merger of two biotech entities.

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• CRISPR Therapeutics: CRISPR Therapeutics is the first commercial-stage CRISPR/Cas9 gene-editing company (Casgevy approval) with a broad pipeline including liver-directed and rare-disease programs. It is a broad incumbent in the gene-editing space relevant to Serapha's monogenic disease focus.
• Sangamo Therapeutics: Sangamo Therapeutics is a clinical-stage genomic medicine company with zinc finger nuclease-based in vivo genome editing programs including liver-directed monogenic disease therapies. As a broad incumbent in genomic medicine, it represents both a peer and a potential acquisition target/partnership candidate.
• Editas Medicine: Editas Medicine is a clinical-stage gene-editing company developing CRISPR/Cas9 and Cas12a therapies for rare genetic diseases. It operates broadly in the same gene-editing category as Serapha Bio and competes for talent, partnerships, and clinical development talent.
• Intellia Therapeutics: Intellia is a clinical-stage CRISPR/Cas9 gene-editing company with programs in liver-directed in vivo editing (NTLA-2001 for ATTR amyloidosis) and other monogenic diseases. As a broader gene-editing incumbent, it competes for the same liver-target patient populations and editing modality space.

Emerging players

• Wave Life Sciences: Wave Life Sciences is a clinical-stage genetic medicines company developing RNA editing (PRISM platform) and antisense oligonucleotides for rare diseases including AATD-adjacent indications. Its RNA-editing modality overlaps with Serapha's gene-editing approach to monogenic disease.
• CAMP4 Therapeutics: CAMP4 Therapeutics is an emerging clinical-stage company developing RNA-based therapeutics that upregulate gene expression to treat rare genetic diseases. While targeting a different mechanism (expression enhancement vs editing), it competes for the same patient populations and rare liver/genetic disease space.

Direct peers

• Korro Bio: Korro Bio is developing RNA editing (ADAR-mediated) therapies for rare diseases including Alpha-1 Antitrypsin Deficiency — directly targeting the same indication as Serapha. Although the modality (RNA editing vs base editing) differs, the indication, delivery, and patient population are essentially identical.
• Prime Medicine: Prime Medicine is a clinical-stage company developing prime editing, a next-generation gene-editing modality closely related to base editing. Both target precise correction of disease-causing mutations in genetic disorders, making Prime a direct platform peer to Serapha's base-editing approach.
• Verve Therapeutics: Verve Therapeutics develops in vivo base-editing and gene-editing therapies delivered via lipid nanoparticles, primarily for cardiovascular disease but with platform overlap in liver-directed monogenic disease editing. Directly comparable to Serapha's LNP-delivered base-editing approach.
• Beam Therapeutics: Beam Therapeutics is the leading clinical-stage base-editing platform company, developing in vivo and ex vivo base-editing therapies for rare and serious diseases. It is the closest direct peer to Serapha Bio given identical base-editing modality and shared focus on monogenic liver-directed disorders.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serapha Bio